Depression as the Middle- and Long-Term Impact for Pre-Symptomatic Testing of Late-Onset Neurodegenerative Disorders: La Depresión como el Indicador de Impacto Psicológico a la Media y Largo Plazo de la Prueba Pre-Sintomática para Enfermedades de Aparición Tardía - A Depressão como Indicador do Impacto Psicológico a Médio e Longo Prazo do Teste Pré-Sintomático de Doenças Neurodegenerativas de Início Tardio by Lêdo, Susana et al.
ISSN 1413-389X Trends in Psychology / Temas em Psicologia – 2016, Vol. 24, nº 2, 579-594
 DOI: 10.9788/TP2016.2-11
Depression as the Middle- and Long-Term Impact 
for Pre-Symptomatic Testing of Late-Onset 
Neurodegenerative Disorders
Susana Lêdo1
Center for Predictive and Preventive Genetics (CGPP),
Institute for Molecular and Cell Biology (IBMC), Porto, Portugal; 
i3S – Instituto de Investigação e Inovação em Saúde, University Porto, Porto, Portugal
Angela Leite
Center for Predictive and Preventive Genetics (CGPP)
Instituto Superior de Ciências Empresariais e do Turismo, Porto, Portugal, 
Faculty of Psychology (ULP), Lusophone University of Oporto, Oporto, Portugal
Teresa Souto
Faculty of Psychology (ULP), Lusophone University of Oporto, Oporto, Portugal
Higher Institute of Social Work of Porto (ISSSP), Porto, Portugal
Maria Alzira Pimenta Dinis
Fernando Pessoa University (UFP)
UFP Energy, Environment and Health Research Unit (FP-ENAS), 
Energy, Environment and Environmental & Public Health Research Laboratories (3ERL), 
Porto, Portugal
Jorge Sequeiros
Center for Predictive and Preventive Genetics (CGPP)
Institute for Molecular and Cell Biology (IBMC), Porto, Portugal; 
i3S – Instituto de Investigação e Inovação em Saúde, University Porto, Porto, Portugal; 
Instituto de Ciências Biomédicas Salazar (ICBAS), Porto, Portugal.
Abstract
This cross-sectional study investigated depression as the middle- (4 years) and long-term (7 and 10 
years) psychological impact of pre-symptomatic testing (PST) for 3 autosomal dominant late-onset 
diseases: Huntington’s disease (HD), Machado-Joseph disease (MJD) and familial amyloidotic poly-
neuropathy (FAP) TTR V30M. It included 203 subjects: 170 (83.7%) underwent the PST for FAP, 29 
(14.3%) for HD and 4 (2%) for MJD. Of these 203, 73 were still asymptomatic carriers, 29 (14.5%) were 
symptomatic, 9 (4.5%) were FAP liver transplanted patients and 89 (44.5%) were non-carriers. Subjects 
were mainly women (58.1%) and married (66.5%). The Beck Depression Inventory (BDI) was used to 
evaluate depression. Scores were higher for symptomatic carriers and for those who have made one or 
more psychological support consultations over the years. For the formers, the mean scores pointed to 
mild depression. Asymptomatic carriers and non-carriers had similar scores but it was impossible to dif-
ferentiate the psychological impact between the medium and long-term. For symptomatic carriers, there 
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were signifi cant differences between the middle- and long-term. The study indicates that depression 
occurs only when subjects had previously manifested the fi rst symptoms of their neurologic disease.
Keywords: Depression, late-onset neurologic diseases, Psychological impact, Pre-symptomatic testing.
A Depressão como Indicador do Impacto Psicológico a Médio 
e Longo Prazo do Teste Pré-Sintomático de Doenças 
Neurodegenerativas de Início Tardio
Resumo
Este estudo transversal investigou a depressão como indicador do impacto psicológico do teste pré-sin-
tomático (TPS) a médio (quatro anos) e longo prazo (de 7 a 10 anos) de doenças neurológicas de início 
tardio: a doença de Huntington (DH), doença de Machado-Joseph (DMJ) e polineuropatia amiloidótica 
familiar PAF (TTR V30M). 203 sujeitos participaram no estudo: 170 (83,7%) submetidos ao TPS para 
PAF, 29 (14,3%) para o DH e 4 (2%) para DMJ. Destes 203, 73 eram portadores assintomáticos, 29 
(14,5%) já eram sintomáticos, 9 (4,5%) pacientes com PAF, já tinham realizado o transplante hepático 
e 89 (44,5%) eram não-portadores. A amostra era constituída maioritariamente por mulheres (58,1%) 
e por sujeitos casados (66,5%). Utilizou-se o Inventário da Depressão de Beck (BDI). Os scores mais 
elevados foram observados nos portadores sintomáticos e nos sujeitos que tinham realizado consultas de 
psicologia com scores indicadores de depressão leve. Os portadores assintomáticos e os não-portadores 
apresentaram médias semelhantes. Para os portadores sintomáticos, encontrámos diferenças signifi cati-
vas entre o médio e o longo prazo. Este estudo conclui que a depressão pode ocorrer nos indivíduos que 
já manifestam os primeiros sintomas da respectiva doença neurológica.
Palavras-chave: Depressão, doenças neurológicas de início tardio, impacto psicológico, teste pré-
sintomático.
La Depresión como el Indicador de Impacto Psicológico 
a la Media y Largo Plazo de la Prueba Pre-Sintomática 
para Enfermedades de Aparición Tardía
Resumen
Este estudio transversal investigó la depresión a la media (4 años) y largo plazo (7 y 10 años) del 
impacto psicológico de la prueba pre-sintomática (PPS) para 3 enfermedades autosómicos, dominantes, 
de aparición tardía: la enfermedad de Huntington (EH), la enfermedad de Machado-Joseph (EMJ) y la
polineuropatia amiloide familiare (PAF) o polineuropatia amiloide da transtiretina FAP (TTR V30M). 
Participaron 203 sujetos: 170 (83,7%) para PPS para PAF, 29 (14,3%) para EH y 4 (2%) para EMJ. De 
estos 203, 73 estaban todavía portador asintomático, 29 (14,5%) eran sintomáticos, 9 (4,5%) fueron 
PAF pacientes con trasplante hepático y 89 (44,5%) eran no-portadores. Eran en su mayoría mujeres 
(58,1%) y casados  (66,5%). Se utilizó el Inventario de Depresión de Beck (IDB). Los puntajes fueron 
mayores para las portadoras sintomáticas y para aquellos que han hecho consultas de apoyo psicológico 
con puntuaciones medias de depresión leve. Los portadores asintomáticos y no portadores tuvieron 
puntajes similares. Para portadores sintomáticos, hubo diferencias signifi cativas entre el medio y largo 
plazo. Este estudio concluye que la depresión puede ocurrir en personas que ya muestran los primeros 
síntomas de la enfermedad neurológica.
Palabras clave: Depresión, enfermedades neurológicas de aparición tardía, impacto psicológico, 
prueba pre-sintomática.
Depression as the Middle- and Long-Term Impact for Pre-Symptomatic Testing 
of Late-Onset Neurodegenerative Disorders.
 581
There are numerous diagnostic or pre-symp-
tomatic tests (PST) for the late-onset neurologi-
cal disorders (LOND) such as Huntington’s dis-
ease (HD), Machado-Joseph disease (MJD) or 
familial amyloidotic polyneuropathy (FAP) TTR 
V30M (MacLeod et al., 2013; Rolim et al., 2006; 
Skirton, Goldsmith, Jackson, & Tibben, 2013; 
Tibben, Timman, Bannink, & Duivenvoorden, 
1997). The use of PST can predict if a person will 
develop the fi rst symptoms sometime in the near 
future (Lerman, 1997; Rolim et al., 2006; Tibben 
et al., 1997). Several studies tried to understand 
the psychosocial short-term impact (i.e., during 
one year, of this type of genetic testing; Codo-
ri, Slavney, Rosenblatt, & Brandt, 2004; Lêdo, 
2002; Lêdo, Leite, & Sequeiros, 2013; Lerman, 
1997; Michie, Bobrow, & Marteau, 2001; Rolim 
et al., 2006; Tibben, 2007; Tibben et al., 1997), 
but very few have studied such impact in the 
middle- and long-term period of time (Decruyen 
et al., 2003, 2004; Gargiulo et al., 2009; Gonza-
lez et al., 2012; Timman, Roos, Maat-Kievit, & 
Tibben, 2004).
During the fi rst year of the predictive 
protocol program, aimed at the short-term 
impact evaluation, developed at the Center for 
Predictive and Preventive Genetics (CGPP) 
at the Institute of Molecular and Cell Biology 
(IBMC), University of Porto, a national 
reference model was evaluated for genetic 
counseling and psychosocial support for people 
at-risk of suffering of such progressive and 
debilitating diseases that have currently no 
effective treatment or cure (Rolim et al., 2006; 
Sequeiros, 1996a). The middle- and long-term 
impact evaluation were studied based on the 
subjects´ initial medical records, considering 
only those subjects who underwent PST for a 
genetic disease.
The Diseases Studied
HD, MJD and FAP are three examples of 
diseases characterized by monogenic autosomal, 
dominant, late-onset, and clinically considered 
as neurodegenerative diseases. These three 
diseases are incurable and highly debilitating, 
and may exhibit a broad spectrum of symptoms 
(Sequeiros, 1996b).
HD (Almqvist, Bloch, & Hayden, 1999; 
Decruyenaere, Evers-Kiebooms, & Van Den 
Berghe, 1997; Tibben, 2007; Tibben et al., 1997) 
is the most studied of the three above mentioned 
neurodegenerative diseases, largely due to its 
early discovery by Guselli and colleagues in 
1983 of the relevant genetic marker (Codori, 
Hanson, & Brandt, 1994). PST for HD began 
in 1986, in Canada and in the United States of 
America (MacLeod et al., 2013; Tibben et al., 
1997), having been extended to Europe at the 
1990’s (Almqvist et al., 1999; Codori et al., 2004; 
Decruyenaere et al., 1997). The literature already 
presents some long-term psychosocial impact 
studies of the HD predictive test (Decruyenaere 
et al., 2003, 2004; Gargiulo et al., 2009; Lêdo 
et al., 2013; Timman et al., 2004). Gargiulo et 
al. (2009) interviewed 119 subjects with PST 
result of non-carriers and carriers after a mean 
delay of 3.7 years of knowing the result of the 
genetic testing they underwent. Depression was 
frequent in asymptomatic carriers (58%). The 
self reported impact of the test showed that 27% 
of non-carriers did not cope well with a favorable 
result, and a signifi cant percentage of non-
carriers (24%) were depressed during the follow-
up period of the test. Only a previous episode 
of depression could be considered a predictive 
factor for later depression after genetic testing, 
in both carriers and non-carriers of the HD 
mutation. Timman et al. (2004) described a 7-10 
years psychological effects of PST for HD in 142 
individuals and their 104 partners. Carriers and 
their partners were more distressed immediately 
after receiving the test result, although their 
outlooks improved somewhat in the 2-3 year 
post-test period. They became, on the contrary, 
more pessimistic when approaching the age of 
onset of the disease. Carriers who felt lost during 
the follow-up period after the disclosure of test 
results, reported more distress on the pre-test 
than the retained carriers. The same authors 
suggested that studies that report few harmful 
effects may have underestimated the real impact 
(Timman et al., 2004). Decruyenaere et al. (2003) 
have carried out a 5 year longitudinal study on 
psychological distress after predictive testing 
for HD and on correlates of post-test distress. 
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Twenty-four carriers and 33 non-carriers have 
participated in the follow-up study. Three points 
in time were included: baseline, 1 year and 5 
years post-test. Five years after the test, the mean 
distress scores of both carriers and non-carriers 
were within the normal range. Carriers did not 
differ from non-carriers in terms of the mean 
general distress. Compared to non-carriers, 
however, carriers had signifi cantly less positive 
feelings and were more consciously avoiding 
HD related situations and thoughts. The authors 
suggested that these fi ndings refl ect the carriers’ 
conscious and unconscious attempt to escape 
from pessimism and to minimize negative con-
sequences of the test result (Decruyenaere et al., 
2003). Psychological distress, 5 years post-test, 
was signifi cantly associated with ego-strength. 
Except for intrusion and avoidance, distress was 
also associated with test motivation. Compared 
with the baseline level, the mean depression, 
general and specifi c anxiety values had 
signifi cantly decreased 1 year and 5 years post-
test. This evolution was independent of the test 
result. The pattern of post-test anxiety differed 
over time, depending on the test motivation. 
Two very specifi c Portuguese diseases, 
MJD and FAP, have also a severe neurodegen-
erative pathway, without effective treatment or 
cure. For MJD, it is important to highlight the 
frequent signs of cerebellar ataxia, progressive 
external ophthalmoplegia and pyramidal signs 
(Coutinho, 1996; Sequeiros, 1996a, 1996b). In 
1993, the gene of MJD was fi nally located on 
chromosome 14 by a group of researchers led by 
Takiyama et al. (1993). This was later confi rmed 
in the Portuguese kindred by Sequeiros (1996c). 
The genetic mutation present in FAP leads to 
the production of an amyloid protein, which is 
immunologically related to transthyretin (TTR) 
that is abnormally degraded, precipitated and 
stored in body tissues as an amyloid substance 
and then deposited in various organs leading 
these patients to experience progressive limita-
tions (Saraiva & Costa, 1986). 
Pre-symptomatic diagnosis for FAP has 
been available since 1984 (Lerman, 1997; Se-
queiros, 1996c). Several psychosocial studies 
have been conducted among families at-risk and 
their descendants in order to study the short-term 
psychosocial impact of their PST (Codori et al., 
2004; Lêdo, 2002; Leite, 2006; Michie et al., 
2001; Paneque et al., 2009; Rolim et al., 2006; 
Tibben et al., 1997) and, in general, no nega-
tive outcomes were shown. There is, however, 
a lack of research concerning the middle- and 
long-term PST psychological impact (Almqvist, 
Brinkman, Wiggins, & Hayden, 2003; Timman 
et al., 2004). Therefore, it becomes important to 
study the middle- and long-term psychological 
impact of information about the genetic status of 
subjects who underwent the PST and compare 
the Portuguese fi ndings with the few foreign 
studies for HD.
The main objective of the research addres-
sed in the present study is to contribute to 
increase the knowledge about the follow-up 
studies investigating the long-term consequences 
of PST, as suggested by Timman et al. (2004), 
in the context of the Portuguese reality that 
includes other diseases of late-onset beyond 
HD. Consequently, symptomatic depression was 
studied and the hypothesis addressed was that the 
levels of depression would increase for carriers 
and decrease for non-carriers in the middle- and 
long-term after PST result disclosure and the 
oncoming age of onset.
Methods and Instruments
This descriptive cross-sectional study was 
based upon the data gathered from the indivi-
dual´s medical records after completing one year 
PST for genetic autosomal dominant late-onset 
diseases (MJD, HD and FAP) in CGPP, at least 
three years before the study, the only criteria 
of inclusion in this study, both for carriers as 
for non-carriers. All subjects who accepted to 
undergo one year protocol, were previously 
informed about the purpose of the research and 
have signed a written consent authorizing the use 
of their data for scientifi c research purposes. The 
guidelines for the investigation were accepted by 
the IBMC ethic committee.
The subjects were contacted only one time, 
during which the socio-demographic question-
naire and the Beck Depression Inventory (BDI) 
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were both fi lled in (Beck, Mendelson, Mock, & 
Erbaugh, 1961; Beck, Steer, Ball, & Ranieri, 
1996).
Participants
A survey and updating was made of the 686 
subjects’ addresses that had completed their 
respective PST protocol at least three years ago, 
before sending the set of specifi c questionnaires 
by mail. Of the 686 subjects, only 203 subjects 
answered, making them effective participants of 
the study.
In terms of the socio-demographic main 
features, and after analyzing Table 1, it is 
possible to observe that 58.1% participants were 
female and that, in terms of age, the majority of 
the participants ranged up to 30 years. Most of 
the subjects who at the completion of the one 
year PST protocol were single, are now actually 
married. Regarding the profession, participants 
had mainly professions that involved some 
responsibilities and had completed higher 
education (1st Graffar Index). Second in range, 
appear those participants that are retired. Most 
subjects underwent the PST for FAP (83.7%) 
and had the carrier genetic status (36.5%). It 
was important to consider, among carriers, 
those who meanwhile became symptomatic for 
their disease (14.5%) and, in the case of FAP, 
if some of these symptomatic patients have 
already had liver transplantation (4.5%). Out 
of the 203 subjects that answered, there was the 
need to establish three cutoff points that signal 
out for how long subjects had been informed 
about their PST result: 32.2% had known their 
genetic status for 4 years, 47% for 7 years and 
20.8% for 10 years.
Chi-Square (χ2) was calculated to assess 
whether there were signifi cant differences 
between the samples at the cutoff points. 
Differences were only found regarding the type 
of disease.
Table 1
Description of the Total Sample by Years of Protocol Disclosure
Variable (n = 203) (%)
Number of Years of Protocol
4 7 10
n % n % n %
Gender
(χ2 = 2.020; df = 2; p = .364)
Female 118 58.1 33 58.1 58 61.1 26 61.9
Male 85 41.9 32 41.9 37 38.9 16 38.1
Age
(χ2 = 9.636; df = 10; p = .473)
≤ 30 years 88 43.3 32 49.2 40 42.1 15 35.7
31 – 40 years 62 30.5 14 21.5 32 33.7 16 38.1
41 – 50 years 20 9.9 7 10.8 10 10.5 3 7.1
51 – 60 years 22 10.8 9 13.8 6 6.3 7 16.7
61 – 70 years 8 3.9 2 3.1 5 5.3 1 2.4
≥ 71 years 3 1.5 1 1.5 2 2.1 0 0.0
Marital status (At PST)
Single 104 51.2
Married 89 43.8
Divorced 5 2.5
Widow 2 1.0
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Variable (n = 203) (%)
Number of Years of Protocol
4 7 10
n % n % n %
Married 132 66.5 30 66.5 65 69.9 30 75.0
Divorced 10 5.0 1 5.0 5 5.4 1 2.5
Widow 3 1.5 0 0.0 2 2.1 1 2.5
Profession
(χ2 = 9.897; df = 14; p = .770)
Retired 40 19.7 15 23.1 15 15.8 10 23.8
Unemployed 19 9.4 7 10.8 8 8.4 4 9.5
Student 15 7.4 4 6.2 9 9.5 2 4.8
1st Graffar index 59 29.1 19 29.2 29 30.5 11 26.2
2nd Graffar index 11 5.4 2 6.2 6 6.3 1 2.4
3rd Graffar index 4 2.0 3 4.6 0 0.0 1 2.4
4th Graffar index 22 10.8 6 9.2 11 11.6 5 11.9
5th Graffar index 33 16.3 7 10.8 17 17.9 8 19.0
Type of Disease
(χ2 = 15.880; df = 4; p = .003)
FAP 170 83.7 46 70.8 84 88.4 39 92.9
HD 29 14.3 15 23.1 11 11.6 3 7.1
MJD 4 2.0 4 6.2 0 0.0 0 0.0
PST Result 
(χ2 = 0.369; df = 2; p = .831)
Non-carrier 91 44.8 30 46.2 43 45.3 17 40.5
Carrier 112 55.2 35 53.8 52 54.7 25 59.5
Current Clinical Status
(χ2 = 4.329; df = 6; p = .632)
Non-carrier 89 44.5 30 46.2 41 44.1 17 41.5
Asymptomatic Carrier 73 36.5 25 38.5 33 35.5 15 36.6
Symptomatic Carrier 29 14.5 9 13.8 15 16.1 5 12.2
Liver Transplanted 
(FAP carriers)
9 4.5 1 1.5 4 4.3 4 9.8
Note. 2 = Chi-Squared Distribution; df = degrees of freedom; p = p-value. PST = pre-symptomatic tests; FAP = 
familial amyloidotic polyneuropathy; HD = Huntington’s disease; MJD = Machado-Joseph disease.
When analyzing Table 1, it is possible to un-
derstand that participants are distributed by the 
three cutoff points of 4, 7 and 10 years. How-
ever, if focusing on the group of subjects who 
completed the protocol seven years ago, the 
mean age increased (31-40 years) and, in terms 
of the profession, the number of retired partici-
pants has also increased.
Instruments
The socio-demographic variables – gender, 
age, profession, and marital status – and a clinical 
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variable – current clinical status – were gathered 
based on the answers to a questionnaire sent to 
the participants (carriers and non-carriers). 
The variable depression was assessed 
using the Portuguese version of BDI (Beck et 
al., 1961; Beck et al., 1996). This inventory was 
translated and adapted since 1973 (Vaz-Serra 
& Pio-Abreu, 1973a, 1973b) and identifi es de-
pression symptoms such as sadness, pessimism, 
sense of failure, dissatisfaction, guilt, expecta-
tion of punishment, disappointment with himself, 
self-criticism, suicidal ideation, tearfulness, irri-
tability, social withdrawal, indecisiveness, body 
image distortion, loss of energy, changes appe-
tite, insomnia, fatigue, weight loss, health con-
cerns and loss of libido (Beck et al., 1996). It is 
a self-response inventory consisting of 21 items, 
designed to measure the severity of depressive 
symptoms. Each item has 4, 5 or 6 statements, 
sorted according to the symptom’s severity, 
which may be none, mild, moderate or severe.
The subject’s task is to choose the statement 
that is closest to its current state. The study of 
BDI psychometric properties showed that it is an 
instrument with good reliability, as mentioned 
by Beck, and also good validity, since Cron-
bach’s alpha (α) is .84 (Pinto-Gouveia, 1990).
Regarding the Portuguese population, Vaz-
Serra and Pio-Abreu (1973a, 1973b) suggested 
that the value of 12 is the cutoff point above 
which the difference between normal and de-
pressed population is set.
Procedure
The work began with the group of subjects 
who signed the written informed consent and had 
completed the PST one year protocol for genetic 
counseling and psychosocial assessment within 
CGPP for more than three years, regardless of 
the subjects being diagnosed as carriers or non-
carriers for the three studied diseases. Then, by 
mail, a set of specifi c questionnaires was sent 
depending on whether the subject was a carrier 
or non-carrier. Besides containing some items 
to update the socio-demographics information, 
as marital status, profession or signifi cant life 
changes, the questionnaires also included some 
questions about the current clinical status – in 
carriers, if a person remained asymptomatic or 
if that person had already presented symptoms 
– and, fi nally, some questions concerning 
the existence of any link to the context of 
the respective disease or, on the contrary, a 
withdrawal from the reality associated with the 
disease, using some psychological scales such 
as BDI. A cover letter containing information 
about the researcher, the nature and objectives 
of the study and recalling the principle of 
confi dentiality displayed when the subject was 
originally registered in the protocol for the PST, 
was also included. 
A period of 6 months was determined to re-
ceive the participant´s responses by mail. After-
wards, those answers were integrated into a da-
tabase, specifi cally developed using IBM SPSS 
Statistics 19.
Data Analysis
The statistical analysis was performed us-
ing the IBM SPSS Statistics 19 (Norusis, 2011). 
Two distinct types of analysis were carried out: 
descriptive and inferential.
In terms of the descriptive analysis, the 
measures used were frequencies, mean, standard 
deviation (SD), and minimum and maximum 
values. In terms of the inferential analysis car-
ried out, it became a necessary complement and 
the options made have included bivariate statisti-
cal analysis – ANOVA and bivariate correlation 
– and prediction for the identifi cation of groups 
– factor analysis and discriminant analysis.
Results
Analysis of the Items Frequency in the Sam-
ple Considering the Gender Variable
The twenty one descriptive items of the scale 
were analyzed considering the mean, SD and 
percentage of symptomatic responses – namely, 
those scored with 1, 2 or 3 points – for the total 
sample and for carriers and non-carriers. It was 
possible to confi rm that there were statistically 
signifi cant differences in relation to item 8 (self-
criticism), item 15 (loss of energy), item 17 
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(fatigue) and item 20 (health concerns), and that 
carriers had higher values  in all items than non-
carriers.
The items presenting higher percentage of 
symptomatic responses were loss of interest, ir-
ritability and fatigue – for carriers – and loss of 
interest, self-criticism and change of sleep pat-
terns – for non-carriers.
When comparing the items’ mean between 
men and women, no statically signifi cant dif-
ferences were found, except regarding crying 
and loss of sexual interest items, which were 
higher in women. This phenomenon is, however, 
common in the general population. 
Descriptive Analysis of BDI Total        
Scores and Subscales
The descriptive analysis of the results of the 
BDI total scores and subscales for: (a) the total 
sample, (b) carriers and non-carriers samples 
and (c) the specifi c samples resulting from the 
three cutoff points considered was performed. 
As it is possible to observe in Table 2, car-
riers presented higher values than non-carriers 
and those differences were statistically signifi -
cant for the BDI total scores (F = 5.138; df = 1; p 
= .025) and for BDI somatic subscale (F = 6.013; 
df = 1; p = .015).
Table 2
Results of the BDI Total Scores and Subscales (M, SD and α) for the Total Sample Carriers and Non-
Carriers Subsamples and Symptomatic and Non-Symptomatic Carriers
Variable
Total sample Carriers Non-carriers
M SD M SD M SD
BDI Total Scores*
6.49 7.95 7.67 8.61 5.08 6.88
(α = .893) (α = .892) (α = .893)
BDI Cognitive-Affective Subscale
3.94 5.35 4.60 5.03 3.13 4.76
(α = .863) (α = .862) (α = .859)
BDI Somatic Subscale*
2.60 3.39 3.14 3.83 1.95 2.65
(α = .769) (α = .785) (α = .711)
Total sample Symptomatic carriers Non-symptomatic carriers
M SD M SD M SD
BDI Total Scores*
6.49 7.95 12.69 9.05 5.26 7.02
(α = .893) (α = .847) (α = .890)
BDI Cognitive-Affective Subscale*
3.94 5.35 6.74 6.25 3.45 4.84
(α = .863) (α = .823) (α = .860)
BDI Somatic Subscale*
2.60 3.39 6.22 4.09 1.76 2.77
(α = .769) (α = .666) (α = .755)
Note. M = Mean; SD = Standard deviation. 
*Differences between carriers and non-carriers and symptomatic and non-symptomatic carriers at p <.05 at p <.05.
In Table 2, it is possible to observe that 
symptomatic carriers presented higher values 
than non-symptomatic carriers and that those 
differences were statistically signifi cant for the 
BDI total scores (F = 18.087; df = 1; p = .001), 
BDI cognitive-affective (F = 7.657; df = 1; p = 
.007) and BDI somatic subscale (F = 38.221; df 
= 1; p = .001).
Concerning the three cutoff points consid-
ered, the means, as well as the SD, were very 
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similar for the BDI total scores and subscales 
(results presented in Table 3) and there are no 
statistically signifi cant differences for the BDI 
total scores, BDI cognitive-affective and BDI 
somatic for the total sample.
The correlations between BDI total scores 
(r = -.027, p = .724) and BDI cognitive-affective 
(r = -.053, p = .465) and BDI somatic (r = .033, 
p = .649) subscales and the cutoffs were calcu-
lated, and it was possible to confi rm that these 
correlations are not signifi cant.
Considering the three cutoff points and the 
test result (carrier and non-carrier), no statistical-
ly signifi cant differences were found regarding 
the BDI total scores, the BDI cognitive-affective 
and the BDI somatic subscales for sample of 
carriers (results presented in Table 4), as well as 
no signifi cant correlations were found between 
BDI total scores (r = -.102, p = .304) and BDI 
cognitive-affective (r = - .117, p = .231) and BDI 
somatic (r = -.045, p = .647) subscales, and the 
cutoff points for this sample.
Taking into account the three cutoff points 
and the current status of individuals, statistically 
signifi cant differences were found for the sample 
of symptomatic carriers relating the BDI total 
scores (F = 4.017, df = 2; p = .032). The differ-
ences found for the BDI cognitive-affective and 
the BDI somatic subscale are, however, not sig-
nifi cant (Table 4). Signifi cant correlations were 
found between the BDI total scores (r = -.506, 
p = .008) and BDI somatic (r = -.447, p = .019) 
and BDI cognitive-affective (r = -.418, p = .030) 
subscales, and the cutoff points for this sample. 
Since these last correlations are negative, it is 
possible to conclude that as time goes by, the 
depression´s value decreases. 
Considering the three cutoff points and 
the current status of carriers (symptomatic 
and asymptomatic), no statistically signifi cant 
differences were found for the sample of 
asymptomatic carriers relating the cutoff points 
in what concerns the BDI total scores, the BDI 
cognitive-affective and BDI somatic subscales 
(Table 4). Similarly, there are no signifi cant 
correlations between BDI total scores (r = 
-.034, p = .778) and BDI cognitive-affective (r 
= -.097, p = .419) and BDI somatic (r = -.081, p 
=.506) subscales, and the cutoff points for this 
sample.
Finally, and taking also into account the 
three cutoff points, no statistically signifi cant 
differences were found considering the cutoff 
points and the BDI total scores, the BDI somat-
ic and the BDI cognitive-affective subscales for 
the sample of non-carriers (results presented in 
Table 5). The correlations between the BDI to-
tal scores (r = -.087, p = .428), and the BDI 
cognitive-affective (r = -.034, p = .757) and 
the BDI somatic subscales (r = .164; p = .131) 
and the cutoff points are not signifi cant for this 
sample.
Table 3
Results of the BDI Total Scores and Subscales (M, SD and α) at the Three Cutoff Points (4, 7 and 10 years) 
for the Total Sample
Variable
4 Years 7 Years 10 Years
M SD M SD M SD
BDI Total Scores
6.63 8.54 6.63 8.00 6.03 7.09
(α = .898) (α = .901) (α = .866)
BDI Cognitive-Affective Subscale
4.19 5.55 4.04 5.60 3.33 4.50
(α = .856) (α = .881) (α = .825)
BDI Somatic Subscale
2.44 3.74 2.68 3.28 2.73 3.12
(α = .810) (α = .778) (α = .680)
Note. M = Mean; SD = Standard deviation. 
* No statistically signifi cant differences were found in relation to the cutoff points regarding the BDI total scores, 
the BDI cognitive-affective and the BDI somatic subscales.
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Table 4
Results of the BDI Total Scores and Subscales (M, SD and α) at the Three Cutoff Points (4, 7 and 10 years) 
for the Carriers (in general) and Symptomatic and Non-Symptomatic Carriers Samples 
4 Years 7 Years 10 Years
Variable M SD M SD M SD
BDI Total Scores*
8.46 9.39 7.93 8.17 5.96 8.38
(α = .893) (α = .885) (α = .909)
BDI Cognitive-Affective Subscale*
5.31 5.94 4.65 5.80 3.43 5.27
(α = .848) (α = .871) (α = .873)
BDI Somatic Subscale*
3.14 4.39 3.43 3.56 2.58 3.53
(α = .815) (α = .756) (α = .779)
For the symptomatic carriers sample
4 Years 7 Years 10 Years
M SD M SD M SD
BDI Total Scores**
18.33 9.03 11.00 8.26 5.50 4.04
(α = .795) (α = .848) (α = .450)
BDI Cognitive-Affective Subscale*
10.00 6.40 5.86 6.20 2.50 1.73
(α = .796) (α = .826) (α = .301)
BDI Somatic Subscale*
8.33 2.55 5.92 3.55 3.20 2.78
(α = .652) (α = .633) (α = .297)
For the non-symptomatic carriers sample
4 Years 7 Years 10 Years
M SD M SD M SD
BDI Total Scores*
5.08 6.97 5.97 7.94 4.13 5.72
(α = .885) (α = .902) (α = .880)
BDI Cognitive-Affective Subscale*
3.84 4.96 3.61 5.28 2.47 3.72
(α = .840) (α = .887) (α = .830)
BDI Somatic Subscale*
1.24 2.55 2.23 3.06 1.67 2.53
(α = .774) (α = .741) (α = .773)
Note. M = Mean; SD = Standard deviation. 
*No statistically signifi cant differences were found in relation to the cutoff points regarding the BDI total scores, 
the BDI cognitive-affective and the BDI somatic subscales; **Differences between cutoff points at p < .05
When analyzing Tables 3 to 5, it is possible 
to observe that, in the total sample, the values 
of the BDI total scores and the BDI cognitive-
affective subscale decrease over the years, 
although slightly. The opposite happens with 
the BDI somatic subscale (Table 3). The same 
happens with the sample of carriers, except for 
the BDI somatic subscale and, for this sample, 
the value of the subscale rises at a cutoff of 
point of 7 years and goes back down at a cut-
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off point of 10 years (Table 4). In relation to 
symptomatic carriers (Table 4), the values  of 
the BDI total scores and the two subscales de-
crease as the years pass. The same happens in the 
sample of non-symptomatic carriers (Table 4), 
although for the BDI total scores and the BDI so-
matic subscale a slight rise occurs at the cutoff 
point of 7 years. Interestingly, in the sample of 
non-carriers, the values of the BDI total scores 
increase as the cutoff points increase as well. 
In relation to the BDI cognitive-affective sub-
scale and the BDI somatic subscale, however, 
the values rise at a cutoff point of 7 years and 
decrease at the cutoff point of 10 years (Table 
5). This fact contradicts the initial hypothesis 
that the depression’s levels would increase for 
carriers and decrease for non-carriers in the 
middle- and long-term psychological impact 
after PST disclosure result and the oncoming 
age of onset of the disease.
Comparison of the Means for the BDI 
Total Scores and the Two Subscales, 
with the Socio-Demographic Variables
The BDI´s means with all independent 
variables were analyzed. For some of them, 
however, no statistically signifi cant values were 
found. That was the case of gender, marital 
status, type of disease, contact with the disease, 
neurological examination and cutoff points. 
Table 5
Results of the BDI Total Scores and Subscales (M, SD and α) at the Three Cutoff Points (4, 7 and 10 years) 
for the Non-Carriers Sample
Variable
4 Years 7 Years 10 Years
M SD M SD M SD
BDI Total Scores
4.41 6.91 5.17 7.64 6.13 4.97
(α = .895) (α = .918) (α = .709)
BDI Cognitive-Affective Subscale
2.83 4.80 3.34 5.35 3.19 3.23
(α = .858) (α = .893) (α = .638)
BDI Somatic Subscale
1.59 2.59 3.43 3.56 2.94 2.49
(α = .758) (α = .790) (α = .458)
Note. M = Mean; SD = Standard deviation. 
*No statistically signifi cant differences were found in relation to the cutoff points regarding the BDI total scores, 
the BDI cognitive-affective and the BDI somatic subscales.
Nevertheless, women presented overall higher 
averages than men, concerning the BDI total 
scores and the two BDI subscales values. 
Signifi cant differences were, however, 
found regarding age, profession, changes in life, 
test result, current state, carriers with symptoms, 
psychological support, and the diffi culty to talk 
about the disease (data presented in Table 6).
As Table 6 shows, carriers present higher 
means in the BDI total scores and the BDI 
somatic subscale values. Regarding the current 
clinical status, it is possible to verify that 
carriers already with symptoms – FAP carriers 
with the disease and which underwent liver 
transplantation – where the ones presenting 
higher means both in the BDI total scores as in 
the BDI subscales scores. It is also worth noting 
that subjects who have never had psychological 
support consultations present lower scores either 
in the BDI total scores or in subscales. It is 
important to highlight that the highest values of 
the BDI total scores and subscales are present on 
those individuals who consider the matter of the 
disease uncomfortable and who have undergone 
substantial changes in their lives.
Regarding the variable profession, pension-
ers and subjects with professions of some re-
sponsibility (3rd Graffar index) are those with the 
highest values for the BDI total scores and for 
BDI subscales.
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Table 6
Mean Comparison for the BDI Total Scores and Subscales, and Socio-Demographic Variables
BDI Total Scores BDI Cognitive-affective Subscale BDI Somatic Subscale
n M F p n M F p n M F p
PST Result
Non-Carrier
Carrier
87 5.08
5.14 .025
87 3.13
3.69 .056
87 1.95
6.01 .015
104 7.67 106 4.60 105 3.14
Current Clinical Status
Non-Carrier
Asymptomatic Carrier
Symptomatic Carrier
Liver Transplanted 
(FAP carriers)
86 5.12
8.54 .001
86 3.14
3.98 .009
86 1.98
17.82 .001
70 5.26 71 3.45 70 1.76
26 12.69 27 6.74 27 6.22
7 11.43 7 6.14 7 5.29
Absence of symptoms (carriers)
Yes
Perhaps
No
65 4.52
14.17 .001
66 3.00
5.18 .001
65 1.48
23.86 .0018 13.88 8 7.50 9 6.11
27 12.89 28 7.11 27 6.11
Psychological Support
Never
Once
Often
53 4.91
6.22 .003
53 2.87
5.33 .006
53 2.04
4.83 .01023 10.04 25 6.08 24 4.13
28 10.96 28 6.57 28 4.39
Uncomfortable Issue
Yes
Perhaps
No
17 9.24
3.40 .021
17 6.35
4.16 .009
17 2.28
1.35 .26613 5.62 13 3.31 13 3.31
55 3.62 55 2.04 55 1.58
Life-Events
Yes
No
52 9.56
5.18 .025
52 5.84
4.99 .028
53 3.72
2.44 .121
52 5.79 54 3.41 52 2.52
Profession
Retired
Unemployed
Student
1st Graffar index
2nd Graffar index
3rd Graffar index
4th Graffar index
5th Graffar index
37 10.51
3.20 .003
37 5.78
1.93 .067
37 4.73
4.34 .001
19 7.53 19 4.79 19 2.74
13 2.77 13 2.08 13 0.69
56 6.86 57 4.33 57 2.47
9 5.56 10 4.40 9 2.44
4 10.25 4 5.50 4 4.75
21 4.67 21 2.43 21 2.24
32 3.09 32 2.00 32 1.09
Note. M = Mean; F = Snedecor’s F distribution or the Fisher–Snedecor distribution; p = p-value. PST = pre-symptomatic tests; 
FAP = familial amyloidotic polyneuropathy.
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Discussion and Conclusions
The results obtained are acceptable consi-
dering the internal consistency of the BDI scale, 
since the α values for all groups of subjects were, 
in general, around .80, leading to the conclusion 
that it is also a valid instrument to study this 
specifi c sample. This high internal consistency 
agrees with what was found in standardization 
studies for the Portuguese population of Vaz-
Serra and Pio-Abreu (1973a, 1973b).
From the performed descriptive analysis, it 
was possible to confi rm what previous studies 
have reported (Bloch, Fahy, Fox, & Hayden, 
1989; Gargiulo et al., 2009; Paneque et al., 
2007), that is, that the female population tends to 
present higher levels of psychopathology and, in 
general, this happens in relation to the depressive 
disorder, which women are more likely to suffer 
than men (Kessler, 2003). Generally, the present 
study shows that the larger number of subjects 
who received the result of carrier present higher 
values of psychopathology – depression, in the 
case – than those receiving the result of non-
carrier, as others studies had already shown 
before (Decruyenaere et al., 2003; Gargiulo et 
al., 2009; Timman et al., 2004).
As previous studies had already reported 
(Broadstock, Michie, & Marteau, 2000; Duis-
terhof, Trijsburg, Niermeijer, Roos, & Tibben, 
2001; Meiser & Dunn, 2000; Tibben et al., 
1997), the presented analysis seems to support 
the idea of a small negative psychological 
impact (middle- and long-term), resulting from 
the completion of PST and knowledge of the 
subjects genetic status. The hypothesis of the 
self-selection which states that individuals 
emotionally and psychologically better prepared 
to perform the PST are those who, in fact, had 
performed it years before, and who return to 
the successive follow-ups (Codori et al., 1994; 
Paneque et al., 2007; Rolim et al., 2006; Tibben, 
2007), seem to continue to explain the tendency 
of the results obtained. Thus, it is possible 
to infer about the possibility of these same 
individuals to be more receptive to respond to 
the questionnaires, years later, as Timman et al. 
(2004) have mentioned. According to the same 
authors, people who continued to attend the 
follow-ups years later, would be those that would 
present less psychological disturbance from 
the beginning and who have never gave up the 
follow-ups, and who did not present avoidance 
mechanisms towards the reality of the disease.
When analyzing the group of carriers 
and focusing on their current status, it could 
be observed that those who have begun in the 
meanwhile to present symptoms, as well as, in 
the case of FAP patients, those who had been 
transplanted, presented average values that 
pointed out to mild depression or very close to 
it, respectively. The mean of non-symptomatic 
carriers were found to be very similar to non-
carriers, corroborating what Licklederer, Wolff, 
and Barth (2008) had also observed, stating that 
no difference between these two conditions 
seem to exist. This fact seems to reveal that 
while representing a reality that is more or less 
distant, and that is more or less expected but 
that has not been yet experienced and, therefore, 
it is not real, the idea of the disease does not 
affect the emotional life of the subjects that only 
when facing the fi rst symptoms, seem to feel 
compelled to encounter this reality and, perhaps, 
to try to mentally and emotionally elaborate it 
for the fi rst time. This point of view becomes 
even more clear, when analyzing the results 
relating the question “Do you continue without 
presenting any symptoms of the disease?”. The 
subjects answering “no” or “maybe” were the 
ones presenting values which revealed mild 
depression (i.e., it seems that to establish the 
existence of symptoms apparently increases the 
degree of depression, although the suspicion of 
the disease existence may already be disturbing 
to the subjects). These fi ndings confi rm the 
reference made in two previous studies of 
Tibben (2007) and Timman et al. (2004) about 
the importance of further investigation on the 
avoidance mechanisms used by carriers that are 
still asymptomatic.
It was found that the individuals who are re-
tired presented higher depression scores and the 
same happened with individuals whose profes-
sion refers to the 3rd Graffar Index - professions 
of medium and technical level. The former may 
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correspond to those individuals already unable 
to work due to the disease. The values found in 
the latter will not be probably related with the 
PST and subsequent genetic status result, but 
only with the valorization of the labor reality that 
is felt as unsatisfactory.
It was also found that individuals who have 
had, over the years, one or more psychological 
consultations, were those presenting the highest 
means, corroborating, once more, the idea that 
they seem to be the ones more disturbed (i.e., 
those who ask for, or use, psychological help).
When faced with the question of the exis-
tence of remarkable life events in recent years, 
the group of carriers confi rming these events 
was the one who presented higher means. The 
fact that these events are mostly described as lost 
or disease of loved ones may be the cause of a 
more depressive experience, which refl ects into 
higher BDI means.
When trying to analyze the mean values of 
the BDI total scores found, depending on the 
time elapsed since the PST, no statistically sig-
nifi cant differences were found when comparing 
carriers with non-carriers, an interesting result. 
The exception happens precisely in the group of 
symptomatic carriers, already sick, where sta-
tistically signifi cant differences were found in 
function of time. Very high values were found, 
on the frontier of moderate depression, in indi-
viduals who underwent the PST for four years 
and already presented symptoms. Patients who 
took the test 7 years ago presented means very 
close to mild depression and the symptomatic 
carriers who performed the PST 10 years ago 
presented much lower mean values very similar 
to the means of non-carriers or asymptomatic 
carriers.
This evidence is important in two situations: 
1. On one hand, how long ago have the sub-
jects performed the PST and, for asymptom-
atic patients, the threat of approaching the 
age at onset of the fi rst symptoms does not 
seem to affect the individuals. Whether the 
subjects live or not with the symptoms of 
the disease;
2. On the other hand, those subjects who had 
apparently little time since the communica-
tion of the result of carrier until the onset 
of the fi rst symptoms are the ones that are 
more depressive. This situation no longer 
occurs for those individuals who performed 
the PST 10 years ago and are, therefore, 
more familiar with the disease.
Limitations of the Study
This study is a cross-sectional one, with 
a possible response limitation, since only 203 
subjects answered out of the 686 contacted, 
and so 70.4% potential participants did not 
integrate the study. The consequence of this 
fact is that no clear conclusions can be drawn 
on the development of the depression. The 
subjects were not monitored for current use of 
antidepressant and/or anxiolytic medication at 
the moment of the evaluation, which may account 
as an attenuating factor, because it contributes 
to minimize the depression. The categorization 
of the time since PST into three different cutoff 
points of 4, 7 and 10 years weakens the study, 
because the differences found at different times 
are not signifi cant.
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